Kleinschmidt K, Troeger A, Foll J, Hanafee-Alali T, Jakob M, Kramer S, et al. Defibrotide for the treatment of veno-occlusive disease/sinusoidal obstruction syndrome in paediatric patients who did not receive haematopoietic stem cell transplantation: case reports of patients from a German academic hospital. EJHaem. 2025;6:e1094. https://doi.org/10.1002/jha2.1094.
Article CAS PubMed PubMed Central Google Scholar
Esposto MP, Milani E, Tridello G, Caddeo G, Bonetti E, Pezzella V et al. Hepatic veno-occlusive disease (VOD) as a complication of hematopoietic stem cell transplantation (HSCT) or after chemotherapy alone in the pediatric population: a single-center experience. In: Proceedings of the EHA 2025 Congress. Milan, Italy: European Hematology Association; 2025.
Escribano-Serrat S, Rodríguez-Lobato LG, Charry P, Martínez-Cibrian N, Suárez-Lledó M, Rivero A, et al. Endothelial activation and stress index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis. Cytotherapy. 2024;26:73–80. https://doi.org/10.1016/j.jcyt.2023.10.008.
Article CAS PubMed Google Scholar
Balaguer-Roselló A, Montoro J, Villalba M, Lizama P, Torres L, Chorão P et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Transplant Cell Ther 2025 https://doi.org/10.1016/j.jtct.2025.05.018.
Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, et al. Exagamglogene autotemcel for transfusion-dependent beta-thalassemia. N Engl J Med. 2024;390:1663–76. https://doi.org/10.1056/NEJMoa2309673.
Article CAS PubMed Google Scholar
Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Thrasher AJ, Hongeng S, et al. Betibeglogene autotemcel gene therapy for non-beta(0)/beta(0) genotype beta-thalassemia. N Engl J Med. 2022;386:415–27. https://doi.org/10.1056/NEJMoa2113206.
Article CAS PubMed Google Scholar
Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2018;53:138–45. https://doi.org/10.1038/bmt.2017.161.
Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379:1301–9. https://doi.org/10.1016/S0140-6736(11)61938-7.
Article CAS PubMed Google Scholar
Xia Y, Qin H, Yang J. Hepatic veno-occlusive disease development in the hematopoietic stem cell transplantation patients: incidence and associated risk factors, a meta-analysis. Eur J Gastroenterol Hepatol. 2021;33:872–84. https://doi.org/10.1097/meg.0000000000001802.
Article CAS PubMed Google Scholar
Vythoulkas D, Tsirigotis P, Griniezaki M, Konstantellos I, Lazana I. Endothelial dysfunction syndromes after allogeneic stem cell transplantation. Cancers 2023;15 https://doi.org/10.3390/cancers15030680.
Mohty M, Malard F, Alaskar AS, Aljurf M, Arat M, Bader P et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl 2023 https://doi.org/10.1038/s41409-023-01992-8.
Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multi-organ failure post stem cell transplantation: a multi-center, randomized, dose-finding trial. Biol Blood Marrow Transpl 2010 https://doi.org/10.1016/j.bbmt.2010.02.009.
McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116–22.
Article CAS PubMed Google Scholar
Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778–83.
Article CAS PubMed Google Scholar
Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl. 2010;16:157–68. https://doi.org/10.1016/j.bbmt.2009.08.024.
Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transpl. 2016;51:403–9. https://doi.org/10.1038/bmt.2015.283.
Corbacioglu S, Kernan NA, Pagliuca A, Ryan RJ, Tappe W, Richardson PG. Incidence of anicteric veno-occlusive disease/sinusoidal obstruction syndrome and outcomes with defibrotide following hematopoietic cell transplantation in adult and pediatric patients. Biol Blood Marrow Transpl. 2020;26:1342–9. https://doi.org/10.1016/j.bbmt.2020.03.011.
Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017;178:112–8. https://doi.org/10.1111/bjh.14727.
Article CAS PubMed PubMed Central Google Scholar
McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–67.
Article CAS PubMed Google Scholar
Ragoonanan D, Khazal SJ, Wang J, Payne A, Kohorst M, Harden A, et al. Improved detection of sinusoidal obstructive syndrome using pediatric-AYA diagnostic criteria and severity grading. Bone Marrow Transpl. 2021;56:175–84. https://doi.org/10.1038/s41409-020-00998-w.
Ragoonanan D, Abdel-Azim H, Sharma A, Bhar S, McArthur J, Madden R, et al. Retrospective analysis of veno-occlusive disease/sinusoidal obstruction syndrome in paediatric patients undergoing hematopoietic cell transplantation—a multicentre study. Lancet Reg Health Am. 2024;33:100728. https://doi.org/10.1016/j.lana.2024.100728.
Article PubMed PubMed Central Google Scholar
Szmit Z, Gorczynska E, Król A, Ussowicz M, Mielcarek-Siedziuk M, Olejnik I, et al. Introduction of new pediatric EBMT criteria for VOD diagnosis: is it time-saving or money-wasting? Prospective evaluation of pediatric EBMT criteria for VOD. Bone Marrow Transpl. 2020. https://doi.org/10.1038/s41409-020-0918-1.
Embaby MM, Rangarajan HG, Abu-Arja R, Auletta JJ, Stanek J, Pai V, et al. Refractory thrombocytopenia is a valid early diagnostic criteria for hepatic veno-occlusive disease in children. Biol Blood Marrow Transpl. 2020;26:546–52. https://doi.org/10.1016/j.bbmt.2019.11.012.
Fussiova M, Svec P, Horakova J, Sedlacek P, Rohon P, Celec P et al. The importance of New EBMT Criteria on the diagnosis of veno-occlusive liver disease in children. J Clin Med 2023;12 https://doi.org/10.3390/jcm12030826.
Trial to Reduce Alloimmunization to Platelets Study G. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337:1861–9 https://doi.org/10.1056/NEJM199712253372601.
Richardson PG, Murakami C, Jin Z, Warren DL, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure; response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337–43.
Article CAS PubMed Google Scholar
Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737–44.
Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transpl. 2004;33:189–95. https://doi.org/10.1038/sj.bmt.1704329.
Corbacioglu S, Honig M, Lahr G, Stohr S, Berry G, Friedrich W, et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transpl. 2006;38:547–53. https://doi.org/10.1038/sj.bmt.1705485.
Corbacioglu S, Topaloglu O, Aggarwal S. A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease/sinusoidal obstruction syndrome. Clin Drug Investig. 2022;42:465–76. https://doi.org/10.1007/s40261-022-01140-y.
Article CAS PubMed PubMed Central Google Scholar
Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica. 2006;91:795–800.
Grupp SA, Corbacioglu S, Kang HJ, Teshima T, Khaw SL, Locatelli F, et al. Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial. Lancet Haematol. 2023. https://doi.org/10.1016/s2352-3026(23)00011-x.
Corbacioglu S, Grupp SA, Richardson PG, Duarte R, Pagliuca A, Ruutu T, et al. Prevention of veno-occlusive disease/sinusoidal obstruction syndrome: a never-ending story and no easy answer. Bone Marrow Transpl. 2023. https://doi.org/10.1038/s41409-023-02007-2.
Comments (0)